Press Releases
Keyword Search
March 3, 2021
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech shares Phase 3 Interim Results of COVAXIN, Demonstrates Efficacy of 81%
Additional Formats
February 23, 2021
European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis
Additional Formats
February 10, 2021
Ocugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common Stock
Additional Formats
February 7, 2021
Ocugen Inc. Announces $23 Million Registered Direct Offering of Common Stock Priced at a Premium to Market
Additional Formats
February 2, 2021
Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market
Additional Formats
January 12, 2021
Ocugen Inc. Announces the Cancellation of Stockholder Meeting Previously Adjourned to 11:00 a.m. Eastern Time on January 13, 2021
Additional Formats
January 8, 2021
Ocugen Inc. Regains Compliance with Nasdaq Bid Price Rule
Additional Formats
January 8, 2021
Ocugen Inc. to Present at CTIC, HC Wainwright and Noble Capital Investor Conferences
Additional Formats